1 / 28

Lezione del 29/04/2005

Lezione del 29/04/2005. Anno accademico 2004/05. Serotonina e farmaci del sistema serotoninergico. Goodman&Gilman’s. Sintesi e metabolismo della serotonina. 5-HT N-acetilase. o-metil- transferasi. melatonina. Il terminale serotoninergico.

maegan
Télécharger la présentation

Lezione del 29/04/2005

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Lezione del 29/04/2005 Anno accademico 2004/05

  2. Serotonina e farmaci del sistema serotoninergico

  3. Goodman&Gilman’s

  4. Sintesi e metabolismo della serotonina 5-HT N-acetilase o-metil- transferasi melatonina

  5. Il terminale serotoninergico

  6. Recettori e meccanismi di trasduzione intracellulare • Esistono almeno 7 tipi di recettori serotoninergici, suddivisi in alcuni sottotipi. • I recettori sono per lo più associati a proteine G (7 domini transmembrana). • Il recettore di tipo 3 (5-HT3) è un recettore canale che trasporta cationi (Na+, K+ con una simile permeabilità, ma può trasportare anche Ca2+)

  7. Recettori serotoninergici

  8. Comparison of the percentage amino acid identity between the different human 5-HT receptor subtypes

  9. Principali recettori 5-HT

  10. Principali recettori 5-HT

  11. Principali recettori 5-HT

  12. Legenda tabelle (*) solo molecole di interesse terapeutico; (**)patologia; (***5-HT1D)Striato, Accumbens, Rafe, nuclei base, ganglio trigemino, m. vasale; (****5-HT1F) Corteccia, talamo, bulbo olfattorio, midollo spinale, utero, mesenteri; (*****5-HT2A) Corteccia, ippocampo, bulbo olfattorio, midollo spinale, s. gastrointestinale, m. vasale e bronchiale, endotelio, piastrine; (******5-HT2C) Plessi coroidei, ponte, striato, ippocampo, ipotalamo, endotelio, m. spinale; (*******5-HT4) Striato, talamo, ippocampo, bulbo olfattorio, plesso mienterico, m. esofagea e vasale; (********5-HT6)Caudato, putamen, accumbens, corteccia, ippocampo, ganglio cervicale superiore; (*********5-HT7) Ippocampo, ipotalamo, talamo, collicolo sup., rafe, gangli simpatici, m. vasale e intestinale S.N= S. Nigra, TSSA= terminali nervosi s. autonomo, Aggres =aggresssività, dep=depressione, almG.I. =alterata motilità gastrointestinale, neuroni sens.= neuroni sensitivi

  13. Spiller R - British Journal of Clinical Pharmacology54 (1), 11-20, 2002

  14. Spiller R- British Journal of Clinical Pharmacology54 (1), 11-20, 2002

  15. Serotonergic modulating drugs for functional gastrointestinal diseases Schematic illustration of selected neuronal and cellular sites where 5HT receptor modulators can act as discussed in the text. 5HT acting via 5HT1p receptors on the gastric inhibitory neurone causes the release of NO which relaxes the gastric fundus. 5HT3 antagonists inhibit splanchnic afferent nerve response to painful distension and inhibit vagal responses to chemotherapy induced 5HT release. They also inhibit discharge of secreto-motor nerves, which act via VIP, and NO. 5HT4 agonists induce peristaltic contractions by stimulating IPAN. These activate ascending excitatory pathways, mediated via acetylcholine and substance P, together with descending inhibitory pathways, mediated via NO and VIP release. Abbreviations: IPAN=intrinsic primary afferent neurone, VIP=Vasoactive intestinal peptide, SP=substance P, NO=nitric oxide.

  16. Cellule enterocromaffini (EC) della mucosa rettale Microvilli Granuli secretori Membrana basolaterale Spiller, Robin - British Journal of Clinical Pharmacology54 (1), 11-20, 2002

  17. Regolazione della secrezione di 5-HT nelle ECs Spiller R - British Journal of Clinical Pharmacology54 (1), 11-20, 2002

  18. Goodman&Gilman’s

  19. Farmaci e sistema serotoninergico: • Recettori 5-HT3: antagonisti come l’ondansetron, il tropisetron, il dolasetron ed il granisetron sono usati come antiemetici nella nausea ed il vomito indotto da farmaci antiblastici Questi farmaci verranno trattati successivamente

  20. Alosetron 2,3,4,5-tetraidro-5-metil-2-[(5-metil-1-H-imidazol-4-yl)metil]-1-H-pirido(4,3-b)indol-1-one, idrocloruro

  21. A Randomized Controlled Clinical Trial of the Serotonin Type 3 Receptor Antagonist Alosetron in Women With Diarrhea-Predominant Irritable Bowel Syndrome • IRRITABLE BOWEL syndrome (IBS) is one of the most common functional gastrointestinal disorders seen in primary care and gastroenterology practices. Irritable bowel syndrome primarily affects women, with prevalence estimates of 14% to 24% of women in the United States and Great Britain. It negatively affects patients' daily activities and quality of life and contributes to significant increases in health care resource utilization … • The serotonin type 3 (5-HT3) receptor antagonists represent valuable therapeutic compounds for the treatment of IBS. The 5-HT3 receptors have been identified on sensory neurons of the gut and mediate reflexes that control gastrointestinal motility and secretion, bowel function, and perception of pain. In patients with IBS, 5-HT3 receptor antagonists increase colonic compliance, slow colonic transit, and improve stool consistency Camilleri et al., Arch Intern Med161 (2001), pp. 1733–1740.

  22. Tegaserod 3-(5-methossi-1H-indol-3-ilmetilene)-N-pentilcarbazimidamide maleato

  23. Tegaserod In the past, treatment decisions were often based on the patient's individual symptoms because there was no single drug that was effective in relieving abdominal pain, bloating and constipation associated with irritable bowel syndrome. However, there is growing evidence that serotonin (5-HT), via its subtype 4 (5-HT4) receptors, plays a pivotal role in the maintenance of overall gastrointestinal motor function. The advent of innovative 5-HT4 receptor agonists has demonstrated that 5-HT4 receptor stimulation can trigger the peristaltic reflex in both animal and human gastrointestinal tract.

  24. Effect of tegaserod versus placebo in patients with irritable bowel syndrome. Müller-Lissner et al., Aliment Pharmacol Ther15 (2001), pp. 1655–1666

  25. Serotonina e controllo dell’appetito Meguid MM et al., Nutrition 16:843-57, 2000

More Related